Development of a Novel <i>Shigella</i> Quadrivalent Conjugate Vaccine Using <i>Shigella</i> O-Polysaccharide and IpaB Carrier Protein.

Vaccines (Basel) · 2026 · PMC12945076 · PMID 41746057

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

flexneri serotypes even showed a trend toward reduced immunogenicity compared with the lower dose ( Figure 5 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Development of a Novel &lt;i&gt;Shigella&lt;/i&gt; Quadrivalent Conjugate Vaccine Using &lt;i&gt;Shigella&lt;/i&gt; O-Polysaccharide and IpaB Carrier Protein.

The sentences

Development of a Novel <i>Shigella</i> Quadrivalent Conjugate Vaccine Using <i>Shigella</i> O-Polysaccharide and IpaB Carrier Protein.